A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2022-10-21
AEs
4
Serious
1
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-26 (study day 81); relationship: Y
severe
serious
assessed
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-02-28 (study day 114); relationship: not assessed; serious criteria: hospitalization
severe
assessed
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-05-17 (study day 192); relationship: not assessed
mild
assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-07-15 (study day 251); relationship: not assessed
Data queries
No data queries.